Updated on 5 September 2012
As a leading multinational healthcare company, we have been collaborating with the Ministry of Health (MoH) over the past years to address the healthcare needs of the Malaysian people. The memorandum of understanding (MoU) reinforces our commitment to the patients in Malaysia and is the result of our continued collaboration with the MoH.
It is the first time that the MoH and a foreign multinational have signed a memorandum for building of healthcare capabilities in Malaysia. We believe that the diversified product portfolio offered by Novartis in Malaysia, which ranges from innovative pharmaceuticals, quality generics, vaccines and diagnostic tools, over-the-counter drugs, animal health and eye care products, has been a contributing factor for the MoH to choose Novartis as a partner for sustainable cooperation.
The MoU aims at building healthcare capabilities in Malaysia and hence it makes a significant contribution to health as National Key Economic Areas (NKEA) and to the overall economic transformation program announced by the MoH in 2010. The proposed areas of cooperation between Novartis and MoH, include the building of technical capabilities; the promotion of clinical trials; the facilitation of access to innovative medicines and quality generic products; and the possible support of healthcare start-up companies by the Novartis Venture Fund.
What is going to be Novartis' contribution towards the partnership?
Novartis and MoH, Malaysia, will explore and evaluate opportunities to cooperate in each of the four key areas that have been identified. As an example, in the building of technical capabilities, the MoH will identify interns to undergo training at Novartis facilities in Switzerland or other suitable locations, for a period of three-to-six months. Moreover, Novartis offers to conduct training and development workshops for government’s key investigators and clinical researchers, who are involved in international research in Malaysia.